Phaseline

Targets › CD59

CD59 (CD59 glycoprotein): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology; next expected readout Aug 2029.

Potent inhibitor of the complement membrane attack complex (MAC) action, which protects human cells from damage during complement activation. Acts by binding to the beta-haipins of C8 (C8A and C8B) components of the assembling MAC, forming an intermolecular beta-sheet that prevents incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore..; FUNCTION: The soluble form from…. (UniProt, P13987)

Open in Phaseline: the race on CD59, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Johnson & Johnson (Janssen)JNJ-81201887
AAV5-delivered CD59 complement regulator
CD59Phase 2Geographic AtrophyAug 2029

Conditions

Geographic Atrophy (1)

Modalities

small molecule (1)

Companies

Johnson & Johnson (Janssen) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.